AG
PBYI icon

Aperio Group’s Puma Biotechnology PBYI Stock Holding History

Aperio Group’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$103K Sell
10,068
-5,971
-37% -$60.5K ﹤0.01% 2379
2020
Q3 		$162K Buy
+16,039
New +$163K ﹤0.01% 2261
2019
Q3 		– Sell
-685
Closed -$9K – 2632
2019
Q2 		$9K Buy
+685
New +$15.8K ﹤0.01% 2798

Other funds holding PBYI

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Aperio Group's PBYI Position: Q4 2020 in Review

Aperio Group reduced its Puma Biotechnology (PBYI) stake by 37% in Q4 2020, selling an estimated $60.5K and leaving 10,068 shares worth $103K. The position accounts for ﹤0.01% of the portfolio, ranked #2379.

Aperio Group first reported a position in PBYI in Q2 2019 and has held it in 3 quarters since. The position peaked at $162K in Q3 2020. 123 funds tracked by Wall St. Rank hold PBYI as of Q4 2020.

  • Aperio Group held 10,068 shares of Puma Biotechnology worth $103K as of Q4 2020.
  • Aperio Group sold 5,971 Puma Biotechnology shares in Q4 2020, an estimated $60.5K.
  • Puma Biotechnology made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2379 holding.
  • Aperio Group first reported a position in Puma Biotechnology in Q2 2019 and has held it in 3 quarters since.
  • Aperio Group's Puma Biotechnology position peaked at $162K in Q3 2020.
  • 123 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.